文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

在最大耐受他汀基础上加用贝派地酸对比安慰剂对心血管高危患者低密度脂蛋白胆固醇的影响:CLEAR Wisdom随机临床试验

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

这项3期随机双盲安慰剂对照试验在北美和欧洲91个中心纳入779例心血管高危患者,按2:1随机接受贝派地酸180 mg每日一次(n=522)或安慰剂(n=257)治疗52周。第12周贝派地酸组LDL-C较基线降低15.1%,安慰剂组升高2.4%,组间差异为-17.4%(95%CI -21.0%至-13.9%,P<.001)。

要点

  • 贝派地酸180 mg每日一次使第12周LDL-C较基线降低15.1%,安慰剂组升高2.4%。
  • 第12周LDL-C组间差异为-17.4%(95%CI -21.0%至-13.9%,P<.001)。
  • 常见不良事件包括鼻咽炎、尿路感染和高尿酸血症。

核心结论

  • 在接受最大耐受他汀的心血管高危患者中,与安慰剂相比加用贝派地酸可在12周内显著降低LDL-C水平。
  • 需要进一步研究评估其持久性、临床效应以及长期安全性。

研究设计与样本

  • 3期随机双盲安慰剂对照临床试验,在北美和欧洲91个临床中心开展,时间为2016年11月至2018年9月,末次随访日期为2018年9月22日。
  • 共779例动脉粥样硬化性心血管疾病和/或杂合子家族性高胆固醇血症患者符合随机化标准,即在接受最大耐受降脂治疗时LDL-C水平≥70 mg/dL(1.8 mmol/L)。
  • 患者按2:1随机接受贝派地酸180 mg每日一次(n=522)或安慰剂(n=257)治疗52周。

主要发现

  • 779例随机化患者平均年龄64.3岁,女性283例(36.3%),740例(95.0%)完成试验。
  • 基线平均LDL-C水平为120.4(SD 37.9)mg/dL。
  • 第12周贝派地酸组LDL-C较基线降低15.1%,安慰剂组升高2.4%,组间差异为-17.4%(95%CI -21.0%至-13.9%,P<.001)。
  • 第12周非高密度脂蛋白胆固醇:贝派地酸组降低10.8%,安慰剂组升高2.3%,差异-13.0%(95%CI -16.3%至-9.8%,P<.001);总胆固醇:降低9.9% vs 升高1.3%,差异-11.2%(95%CI -13.6%至-8.8%,P<.001);载脂蛋白B:降低9.3% vs 升高3.7%,差异-13.0%(95%CI -16.1%至-9.9%,P<.001);高敏C反应蛋白中位数:降低18.7% vs 降低9.4%,差异-8.7%(渐近置信限-17.2%至-0.4%,P=.04)。
  • 常见不良事件:鼻咽炎在贝派地酸组为5.2%、安慰剂组为5.1%;尿路感染为5.0% vs 1.9%;高尿酸血症为4.2% vs 1.9%。

局限性

  • 需要进一步研究评估其持久性、临床效应以及长期安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Additional treatment options are needed for patients who do not achieve sufficient reduction in low-density lipoprotein cholesterol (LDL-C) level with available lipid-lowering therapies. OBJECTIVE: To assess the efficacy of bempedoic acid vs placebo in patients at high cardiovascular risk receiving maximally tolerated lipid-lowering therapy. DESIGN, SETTING, AND PARTICIPANTS: Phase 3, randomized, double-blind, placebo-controlled clinical trial conducted at 91 clinical sites in North America and Europe from November 2016 to September 2018, with a final date of follow-up of September 22, 2018. A total of 779 patients with atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or both met randomization criteria, which included LDL-C level 70 mg/dL (1.8 mmol/L) or greater while receiving maximally tolerated lipid-lowering therapy. INTERVENTIONS: Patients were randomized 2:1 to treatment with bempedoic acid (180 mg) (n = 522) or placebo (n = 257) once daily for 52 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was percent change from baseline in LDL-C level at week 12. Secondary measures included changes in levels of lipids, lipoproteins, and biomarkers. RESULTS: Among 779 randomized patients (mean age, 64.3 years; 283 women [36.3%]), 740 (95.0%) completed the trial. At baseline, mean LDL-C level was 120.4 (SD, 37.9) mg/dL. Bempedoic acid lowered LDL-C levels significantly more than placebo at week 12 (-15.1% vs 2.4%, respectively; difference, -17.4% [95% CI, -21.0% to -13.9%]; P < .001). Significant reductions with bempedoic acid vs placebo were observed at week 12 for non-high-density lipoprotein cholesterol (-10.8% vs 2.3%; difference, -13.0% [95% CI, -16.3% to -9.8%]; P < .001), total cholesterol (-9.9% vs 1.3%; difference, -11.2% [95% CI, -13.6% to -8.8%]; P < .001), apolipoprotein B (-9.3% vs 3.7%; difference, -13.0% [95% CI, -16.1% to -9.9%]; P < .001), and high-sensitivity C-reactive protein (median, -18.7% vs -9.4%; difference, -8.7% [asymptotic confidence limits, -17.2% to -0.4%]; P = .04). Common adverse events included nasopharyngitis (5.2% vs 5.1% with bempedoic acid and placebo, respectively), urinary tract infection (5.0% vs 1.9%), and hyperuricemia (4.2% vs 1.9%). CONCLUSIONS AND RELEVANCE: Among patients at high risk for cardiovascular disease receiving maximally tolerated statins, the addition of bempedoic acid compared with placebo resulted in a significant lowering of LDL-C level over 12 weeks. Further research is needed to assess the durability and clinical effect as well as long-term safety. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02991118.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019. PMID: 31714986. doi:10.1001/jama.2019.16585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。